History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.

Published

Journal Article

BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited. METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer. RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival. CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

Full Text

Duke Authors

Cited Authors

  • Minlikeeva, AN; Freudenheim, JL; Cannioto, RA; Eng, KH; Szender, JB; Mayor, P; Etter, JL; Cramer, DW; Diergaarde, B; Doherty, JA; Dörk, T; Edwards, R; deFazio, A; Friel, G; Goodman, MT; Hillemanns, P; Høgdall, E; Jensen, A; Jordan, SJ; Karlan, BY; Kjær, SK; Klapdor, R; Matsuo, K; Mizuno, M; Nagle, CM; Odunsi, K; Paddock, L; Rossing, MA; Schildkraut, JM; Schmalfeldt, B; Segal, BH; Starbuck, K; Terry, KL; Webb, PM; Zsiros, E; Ness, RB; Modugno, F; Bandera, EV; Chang-Claude, J; Moysich, KB

Published Date

  • September 26, 2017

Published In

Volume / Issue

  • 117 / 7

Start / End Page

  • 1063 - 1069

PubMed ID

  • 28817835

Pubmed Central ID

  • 28817835

Electronic International Standard Serial Number (EISSN)

  • 1532-1827

Digital Object Identifier (DOI)

  • 10.1038/bjc.2017.267

Language

  • eng

Conference Location

  • England